Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness

NCT05677763 is registered in ClinicalTrials.gov with OM Pharma SA as lead sponsor.

NCT NCT05677763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness
Lead sponsor
OM Pharma SA
Phase
Phase 4
Overall status
Completed
Start date
December 12, 2022
Completion date
September 16, 2026
Enrollment
525 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory tract infections, wheezing lower respiratory illness